Hologic Acknowledges Results of the Digital Mammography Imaging Screening Trial Have Been Published

BEDFORD, Mass., Sep. 16, 2005 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of state-of-the-art digital imaging systems directed towards women's health, today acknowledged the results of the Digital Mammography Imaging Screening Trial (DMIST), which have been published in the New England Journal of Medicine. Detailed information regarding these results can be found in the on-line version of the journal at

DMIST was a four-year research study sponsored by the National Cancer Institute to compare digital mammography to conventional screen-film mammography. The primary purpose of the study was to determine whether digital mammography was the equivalent of, or better than conventional screen-film. ACRIN, The American College of Radiology Imaging Network coordinated the study, which consisted of approximately 49,500 participants in both the U.S. and Canada. Digital mammography takes an electronic image of the breast and stores it directly in a computer allowing the recorded data to be magnified, enhanced or manipulated for further evaluation.

The article published today in The New England Journal of Medicine found that in the entire population, the diagnostic accuracy of digital and film mammography was similar, however, the accuracy of digital mammography was significantly higher than that of film mammography among women under the age of 50 years, women with heterogeneously dense or extremely dense breasts on mammography and premenopausal or perimenopausal women.

"We are pleased with the results of the DMIST study and commend the trial's principal investigator, Dr. Etta Pisano and all the clinicians, technologists, statisticians, and support team of ACRIN who dedicated themselves to this significant research study," said Jack W. Cumming, Hologic's Chairman and Chief Executive Officer. "The most promising finding involved a subcategory of women including women under 50, women with dense breasts and premenopausal or perimenopausal women, which represented 65% of the study population, digital mammography had statistically greater diagnostic accuracy than film-based systems. In the U.S., breast cancer mortality is second only to that of lung cancer. For women ages 40-55, it is the leading cause of death. Hologic remains dedicated to increasing awareness of breast cancer, especially the importance of early detection through screening mammography. We believe the DMIST findings will further promote the use of digital mammography and help provide women with more options for high quality breast imaging."

About Hologic

Hologic Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to- digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications. For more information visit

Forward Looking Disclaimer

This News Release contains forward-looking information that involves risks and uncertainties, including statements about benefits expected to result from the DMIST findings and any implication that the DMIST findings may be indicative of future sales. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause Hologic's actual results to materially differ include, without limitation, the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the ability of Hologic's sales force to successfully service its product offerings; Hologic's ability to successfully manage current or future alliances or joint ventures; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, such as the ability to obtain FDA approval to market products developed, cost overruns and delays; the early stage of market development for the technologies and products anticipated to be developed and distributed; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; the need to comply with especially high standards in the manufacture of medical products; technical innovations that could render the technology or products under development obsolete; competition; and reimbursement policies for the use of products, if and when developed. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.

   Glenn P. Muir                           Frances Crecco
   Executive Vice President & CFO          Director, Investor Relations
   Hologic, Inc.                           Hologic, Inc.
   (781) 999-7300                          (781) 999-7377

SOURCE: Hologic, Inc.

CONTACT: Glenn P. Muir, Executive Vice President & CFO, +1-781-999-7300,
or Frances Crecco, Director, Investor Relations, +1-781-999-7377, both of
Hologic, Inc.

Web site: